Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
0.5886
-0.0035 (-0.59%)
At close: Apr 2, 2025, 4:00 PM
0.5771
-0.0115 (-1.95%)
After-hours: Apr 2, 2025, 7:00 PM EDT

Company Description

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines.

It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.

The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.

It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer.

The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Psyence Biomedical Ltd.
Psyence Biomedical logo
Country Canada
Founded 1994
Industry Biotechnology
Sector Healthcare
CEO Neil Maresky

Contact Details

Address:
121 Richmond Street West, Penthouse Suite, 1300
Toronto, ON M5H2K1
Canada
Phone 416-346-7764
Website psyencebiomed.com

Stock Details

Ticker Symbol PBM
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001985062
ISIN Number CA74449F1009
SIC Code 2834

Key Executives

Name Position
Dr. Neil Maresky M.D. Chief Executive Officer and Director
Jody Aufrichtig Co-Founder, Executive Chairman and Strategic Business Development Officer
Warwick Ron Corden-Lloyd Chief Financial Officer
Taryn Vos General Counsel

Latest SEC Filings

Date Type Title
Apr 1, 2025 6-K Report of foreign issuer
Mar 31, 2025 6-K Report of foreign issuer
Mar 25, 2025 SCHEDULE 13D/A Filing
Mar 14, 2025 EFFECT Notice of Effectiveness
Mar 4, 2025 F-3 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 10, 2025 SCHEDULE 13G/A Filing
Feb 10, 2025 SCHEDULE 13G Filing
Jan 30, 2025 EFFECT Notice of Effectiveness
Jan 30, 2025 424B3 Prospectus